Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Dry Eye (Aug 2019)

Posted by Matt Breese on Aug 30, 2019

Find me on:

According to our recent payer coverage analysis for dry eye treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for dry eye treatments shows that under the pharmacy benefit, about 40% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Dry EyeData snapshot as of Q2 2019

Trends: Contracting for preferred formulary status is expected to expand as new agents are approved. Many payers do not allow coverage for compounded products, so Klarity-C may have access issues.    

To read the full Reality Check on Dry Eye treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing